Cory Lewis

Discover the Validator difference! 🌟 1. We live and breathe validation in the industry, giving us a deep understanding of the current landscape and making us experts at what we do. Get industry best practices reflected in our daily work for top-notch results! 2. Validator is designed with CSA principals at its core, focusing on critical thinking and risk assessment over drowning in unnecessary documentation. Experience true efficiency with our approach! 3. Automate your validation process from start to finish with Validator's cutting-edge philosophy. By managing data components and content effectively, we ensure maximum compliance with minimum effort and time. Embrace flexibility and reusability like never before! 💡 #ValidatorDifference"

21

Use of #PBPK modeling early in drug development has become popular. We can utilize this approach for lead candidate selection and designing first-in-human formulation development pathway. Using #GastroPlus early has been found to accelerate drug development in a material sparing way, and saves time and money. #drugdevelopment #formulationdevelopment #cmc #research

17

Does this Abstract from 2007 suggest that there may have been concerns about H5N1, SARS- CoV and our ability to content them long ago? What have we learned thus far? And what plan of action should be taken at this point? Remember, ignorance is no defense, we have been warned. What you see here is another a small sample of the possibilities of 222nm and the many benefits of this technology. PubMed 2007 Jan;61(1):41-5.  doi: 10.1055/s-2006-955002. [Avian influenza and the Severe Acute Respiratory Syndrome (SARS) - experiences and perspectives] [Article in German] G Hoheisel 1, W K Luk, J Winkler, H Wirtz, A Gillissen, D S Hui, U G Liebert https://lnkd.in/ddQzfWbP Abstract New respiratory viruses associated with pneumonia have in the past few years been detected in humans. The sudden appearance of the severe acute respiratory syndrome (SARS) in 2003 demonstrated that an emerging and highly infectious disease caused by a hitherto unknown virus was able to spread rapidly, but could finally be contained by stringent measures. The avian influenza A-H5N1-virus of high pathogenicity has crossed in multiple instances the species barriers between humans, mammals, and birds posing a serious pandemic threat. The application of the so far learnt and the continued development of preventive strategies, efficient vaccines, and antiviral substances are besides worldwide surveillance decisive to rapidly detect the repeated, enforced, or new appearance of viruses like the SARS-CoV, influenza A-H5N1 virus, or of new viruses, to contain their spread, and to defeat them. Recent related News… Inadequate bird flu testing is making pandemic experts concerned we're "flying blind" with H5N1 Story by Nicole Karlis  • 3d • 5 min read https://lnkd.in/dbCDZyCX Sentence from this article: “But now, a new study suggests that dairy cows might have the same potential as pigs, which could improve the bird flu’s capability of being more human-to-human transmission.” #222nm #airborneviruses #fda

3

Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per year for five years, it said Monday morning. The drugmaker is the exclusive limited partner for the fund, which launched this month under the name Regeneron Ventures. It will invest in biotech startups, devices, tools and “enabling technologies.” Jay Markowitz #venturefunding #financing #pharma #pharmaceuticals #biotech #biotechnology #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #startups #tools #technologies #devices #enablingtechnologies #lifesciences

394

4 Comments